ArticleCancers2021
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Integrated molecular dynamics elucidation of TP53 H179 zinc-binding variants: genomic and structural characterization across NSCLC subtypes.Frontiers in bioinformatics · 2026Article
- A Patient-Derived Organoid Platform from TUR-P Samples Enables Precision Drug Screening in Advanced Prostate Cancer.Cancers · 2025Article
- Downregulation of the Tumor Suppressor P53 Gene associated with the Progression of Clinical Staging and the Incidence of Distant Metastasis in Indonesian Colorectal Cancer.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Article
- Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors.JAMA network open · 2025Article
- Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies.The oncologist · 2025Article
- Comprehensive genomic profiling of small bowel adenocarcinoma with liver metastasis.Journal of gastrointestinal oncology · 2025Article
- The Role of Monoclonal Antibodies as Therapeutics in HPV-Related Head and Neck Cancers: An Updated Review.Antibodies (Basel, Switzerland) · 2025Review
- Comprehensive analysis of the pituitary tumor-transforming gene (PTTG) family in lung adenocarcinoma: diagnostic, prognostic, and therapeutic implications.American journal of translational research · 2024Article
- Article
- Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.Journal of inflammation research · 2023Article
- A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma.Translational andrology and urology · 2022Article
- Text-Mining Approach to Identify Hub Genes of Cancer Metastasis and Potential Drug Repurposing to Target Them.Journal of clinical medicine · 2022Article
- Melanoma in patients with Li-Fraumeni syndrome (Review).Experimental and therapeutic medicine · 2022Review
- Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer.Journal of oncology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
Molecular profiling with next generation sequencing (NGS) delivers key information on mutant gene sequences, copy number alterations, gene-fusions, and with immunohistochemistry (IHC), is a valuable tool in clinical decision making for patients entering investigational agent trials. Our objective was to elucidate mutational profiles from primary versus metastatic sites from advanced cancer patients to guide rational therapy. All phase I patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.